Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New research published today in eLife demonstrates a new function for Wiskott-Aldrich Syndrome (WAS) protein in the activation of T cells, which play a central role in our immune system.

New research published today in eLife demonstrates a new function for Wiskott-Aldrich Syndrome (WAS) protein in the activation of T cells, which play a central role in our immune system.

The study, led by Professor Michael Dustin of the Kennedy Institute, NDORMS in collaboration with Dr Sudha Kumari at MIT furthers our understanding of the regulation of T cell activation – an essential part of our immune response to different types of diseases – and its dysfunction in WAS patients.

WAS is a rare serious disease affecting between 1 and 10 people in a million worldwide, usually male (90%). People suffering from WAS have abnormal or nonfunctional white blood cells (which are part of the immune system) and are at increased risk of developing several immune and inflammatory disorders. There is also a significant reduction in the size and number of platelets, causing those affected to bleed easily.

The condition is caused by mutations or defects in the WAS gene, responsible for giving the instruction to make the Wiskott-Aldrich Syndrome Protein (WASP).  WASP is known to be able to produce new actin cytoskeleton, a network of fibers that make up the cell's structural framework.  The new research identifies how WASP is involved in passing on signals from the surface of T cells through the actin cytoskeleton to the cells core.

Professor Dustin says: “This was a heroic effort by Dr. Kumari, which required an arsenal of new tools. This effort opens a way forward to much needed new therapeutics for WAS and more common immunological diseases such as allergies.”

Similar stories

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.

NDORMS academics named NIHR Senior Investigators

Main

Congratulations to Professor Jonathan Rees who has been announced as a National Institute of Health Research (NIHR Senior Investigator).